Solidaginis virgaureae herba
European Goldenrod
Solidago virgaurea L.
PDF format
Descargar la monografía (Pdf) 15¤ para el público en general, 12¤ para los socios de SEFIT
Visualizar las monografías de ESCOP (30¤/año, gratis para los socios de SEFIT)
The herbal monograph selects and summarises scientific studies and
textbooks regarding efficacy, dosage and safety to support the
therapeutic uses of European goldenrod.
This herbal drug by definition consists of the whole or fragmented, dried, flowering aerial parts of Solidago virgaurea L.
Studies with its main characteristic constituents: flavonoids,
triterpene saponins, phenol diglucosides and phenolic acids are
included.
The therapeutic indications are irrigation of the urinary
tract, especially in cases of inflammation and renal gravel and as an
adjuvant in the treatment of bacterial infections of the urinary tract.
Administration of European goldenrod addresses posology; its
duration of use; contra-indications; special warnings; special
precautions for use; interactions with other medicinal products; other
forms of interaction; in pregnancy and lactation; its effects on ability
to drive; undesirable effects; overdose.
In vitro experiments with European goldenrod demonstrated spasmolytic, anti-inflammatory and diuretic effects.
In vivo experiments with European goldenrod or its extracts demonstrated diuretic, anti-inflammatory and analgesic properties.
Pharmacological studies in humans concern diuretic activities.
Controlled clinical studies with European goldenrod preparations
demonstrated its use as a diuretic in patients with urinary tract
infections.
Pharmacokinetics of orally administered leiocarposide was assessed in animals.
Preclinical safety data were assessed in toxicity studies. Safety data were assessed in human studies. A good tolerability was reported.
The selection of literature cited in the monograph is aimed at bringing
together relevant information about the possible physiological roles of
European goldenrod and its major constituents.